Chimeric antigen receptor (CAR) T cell (CAR-T cell) therapy based on gene editing
technology represents a significant breakthrough in personalized immunotherapy for human …

Immunotherapies have become the backbone of cancer treatment. Among them, chimeric
antigen receptor (CAR) T cells have demonstrated great success in the treatment of …

T-cells have a natural ability to fight cancer cells in the tumour microenvironment. Due to
thymic selection and tissue-driven immunomodulation, these cancer-fighting T-cells are …

Chimeric antigen receptor (CAR) T cell therapy is a promising cancer treatment that has
recently been undergoing rapid development. However, there are still some major …

Chimeric antigen receptor (CAR) T cell therapy has been successful in treating B cell
malignancies in clinical trials; however, fewer studies have evaluated CAR T cell therapy for …

Chimeric antigen receptor (CAR)-T cell therapy has had unprecedented impact in the
treatment of hematological malignancies with few therapeutic options. However, it is clear …

Cancer immunotherapies utilizing genetically engineered T cells have emerged as powerful
personalized therapeutic agents showing dramatic preclinical and clinical results …

During this last decade, adoptive transfer of T lymphocytes genetically modified to express
chimeric antigen receptors (CARs) emerged as a valuable therapeutic strategy in …

Background: Chimeric antigen receptor (CAR)-modified T cells have successfully harnessed
T cell immunity against malignancies, but they are by no means the only cell therapies in …

Genetic redirection of T lymphocytes with chimeric antigen receptors (CARs) has soared
from treating cancers preclinically to FDA approval for hematologic malignancies and …